what is the unique, simple, and official name assigned to a specific drug for worldwide use?
Int J Pharm Investig. 2012 January-Mar; 2(i): ii–11.
Drug delivery systems: An updated review
Gaurav Tiwari
Section of Pharmaceutics, Pranveer Singh Institute of Technology, Kanpur, Uttar Pradesh, India
Ruchi Tiwari
Department of Pharmaceutics, Pranveer Singh Institute of Technology, Kanpur, Uttar Pradesh, Republic of india
Birendra Sriwastawa
1 Department of Pharmaceutics, Jaipur National Academy, Jagatpura, Jaipur, Rajasthan, India
Fifty Bhati
2 Mankind Research Middle, Manesar, Gurgaon, Republic of india
Due south Pandey
Department of Pharmaceutics, Pranveer Singh Institute of Technology, Kanpur, Uttar Pradesh, Republic of india
P Pandey
Department of Pharmaceutics, Pranveer Singh Constitute of Applied science, Kanpur, Uttar Pradesh, India
Saurabh K Bannerjee
3 Section of Pharmaceutics, SVKM'southward Narsee Monjee Found of Management Studies (NMIMS), Schoolhouse of Chemist's shop and Technology Direction, Dhule, Maharashtra, Republic of india
Abstract
Drug delivery is the method or process of administering a pharmaceutical compound to achieve a therapeutic issue in humans or animals. For the treatment of human diseases, nasal and pulmonary routes of drug delivery are gaining increasing importance. These routes provide promising alternatives to parenteral drug delivery especially for peptide and protein therapeutics. For this purpose, several drug delivery systems have been formulated and are existence investigated for nasal and pulmonary delivery. These include liposomes, proliposomes, microspheres, gels, prodrugs, cyclodextrins, amongst others. Nanoparticles composed of biodegradable polymers show balls in fulfilling the stringent requirements placed on these delivery systems, such as ability to be transferred into an aerosol, stability against forces generated during aerosolization, biocompatibility, targeting of specific sites or cell populations in the lung, release of the drug in a predetermined manner, and degradation within an adequate period of time.
Keywords: Brain targeting, infectious diseases, liposomal, lung diseases, micelles, transdermal
INTRODUCTION
Development of new drug molecule is expensive and fourth dimension consuming. Improving safety efficacy ratio of "onetime" drugs has been attempted using unlike methods such as individualizing drug therapy, dose titration, and therapeutic drug monitoring. Delivering drug at controlled charge per unit, dull delivery, targeted commitment are other very attractive methods and take been pursued vigorously. It is interesting to notation that considerable piece of work and many publications from The states, Europe are authored by Indian researchers.[i–3] Numerous animal and man investigations take provided an increased agreement of the pharmacokinetic and pharmacodynamic principles that govern the action and disposition of stiff opioid analgesics, inhalation anesthetic agents, sedative/hypnotics, and muscle relaxants. These studies suggest that peel and buccal and nasal mucous membranes may accept use every bit alternate routes of analgesic and coldhearted delivery. Similar developments with other compounds take produced a plethora of new devices, concepts, and techniques that have together been termed controlled-release technology (CRT). Some examples of CRTs are transdermal and transmucosal controlled-release delivery systems, ml6 nasal and buccal aerosol sprays, drug-impregnated lozenges, encapsulated cells, oral soft gels, iontophoretic devices to administer drugs through skin, and a variety of programmable, implanted drug-delivery devices. There are a number of factors stimulating involvement in the development of these new devices, concepts, and techniques. Conventional drug assistants methods, while widely utilized, have many problems that may be potentially overcome past these methods. Equally important, these advances may appear attractive relative to the costs of new drug development. Rise research and development costs, culling investment opportunities for drug firms, fewer firms conducting pharmaceutical research, and erosion of effective patent life have resulted in a refuse in the introduction of new chemical entities since the late 1950s. Bringing a new drug through discovery, clinical testing, development, and regulatory blessing is currently estimated to take a decade and price well over $ 120 million. Novel drug delivery systems may business relationship for as much as twoscore% of US marketed drug products by 2000.[4–6]
BEADED Commitment SYSTEMS
Although not used with oxybutylin, beaded delivery formulations are another method used to reach long-interim drug levels associated with the convenience of once-a-day dosing. This system has been successfully linked to tolterodine tartrate and is available as Detrol LA (Pharmacia, Peapack, NJ). Essentially, the beaded system consists of multiple, small chaplet that are composed of inert substances (such as polystyrene). The agile drug is overlaid on the chaplet and encased in a delivery capsule. The drug delivery from this system is acid sensitive, in that drug levels are dependent on gastric acidity for release. This process produces a pharmacokinetic pattern roughly similar to a zero-order pattern, with C max obtained approximately 4 to 6 hours afterward ingestion and sustained levels observed for 24 hours after initial dosing. Comparative advantages are seen for both efficacy (improved incontinence rates) and tolerability with Detrol LA over immediate-release tolterodine. In a double-blind, placebo-controlled, randomized study of 1529 patients the LA formulation resulted in 18% less incontinence episodes than the immediate-release tolterodine, whereas both formulations were statistically superior to placebo in reducing urinary frequency and increasing voided urinary volume. The overall dry out mouth rate was 23% lower for tolterodine LA than immediate-release tolterodine. Rates of withdrawal were similar beyond all arms. Van Kerrebroeck concluded that the LA conception of tolterodine was superior to the firsthand-release formulation.[vii–8]
LIPOSOMAL AND TARGETED DRUG DELIVERY System
Drug delivery systems can in principle provide enhanced efficacy and/or reduced toxicity for anticancer agents. Long circulating macromolecular carriers such as liposomes can exploit the 'enhanced permeability and retention' effect for preferential extravasation from tumor vessels.[4] Liposomal anthracyclines take achieved highly efficient drug encapsulation, resulting in meaning anticancer activeness with reduced cardiotoxicity, and include versions with greatly prolonged circulation such every bit liposomal daunorubicin and pegylated liposomal doxorubicin. Pegylated liposomal doxorubucin has shown substantial efficacy in breast cancer treatment both every bit monotherapy and in combination with other chemotherapeutics. Additional liposome constructs are being developed for the delivery of other drugs. The next generation of delivery systems will include true molecular targeting; immunoliposomes and other ligand-directed constructs stand for an integration of biological components capable of tumor recognition with delivery technologies.[5]
As discussed, currently approved liposomal drug delivery systems provide stable formulation, provide improved pharmacokinetics, and a degree of 'passive' or 'physiological' targeting to tumor tissue.[6] Nonetheless, these carriers exercise not straight target tumor cells. The design modifications that protect liposomes from undesirable interactions with plasma proteins and cell membranes, and which dissimilarity them with reactive carriers such as cationic liposomes, also prevent interactions with tumor cells. Instead, later extravasation into tumor tissue, liposomes remain inside tumor stroma every bit a drug-loaded depot. Liposomes eventually become bailiwick to enzymatic degradation and/or phagocytic attack, leading to release of drug for subsequent diffusion to tumor cells. The next generation of drug carriers under development features straight molecular targeting of cancer cells via antibody-mediated or other ligand-mediated interactions.
Immunoliposomes, in which mAb fragments are conjugated to liposomes, stand for a strategy for molecularly targeted drug delivery.[9] Anti-HER2 immunoliposomes have been developed with either Fab' or scFv fragments linked to long-circulating liposomes. In preclinical studies, anti-HER2 immunoliposomes bound efficiently to and internalized in HER2-overexpressing cells, resulting in efficient intracellular delivery of encapsulated agents. Anti-HER2 immunoliposomes loaded with doxorubicin displayed potent and selective anticancer activity against HER2-overexpressing tumors, including significantly superior efficacy versus all other treatments tested (gratuitous doxorubicin, liposomal doxorubicin, free mAb [trastuzumab], and combinations of trastuzumab plus doxorubicin or liposomal doxorubicin).[10] Anti-HER2 immunoliposomes are currently undergoing scale up for clinical studies.[9,11]
The immunoliposome approach offers a number of theoretical advantages as compared with other antibiotic-based strategies. Anti-HER2 immunoliposome delivery of doxorubicin may circumvent the prohibitive cardiotoxicity associated with combined trastuzumab plus doxorubicin handling. Anti-HER2 immunoliposomes can be constructed using scFv that, unlike trastuzumab, lack antiproliferative activity, are incapable of antibody-dependent cellular cytotoxicity, and require threshold levels of HER2 expression for delivery. In dissimilarity to drug immunoconjugates, which consist of a small number of drugs (typically <x drugs per mAb) straight coupled via linkers to selected residues on the mAb, immunoliposomes exploit the exponentially greater chapters of drug-loaded liposomes (upwards to 10four drugs per liposome). Immunoliposomes also announced to be nonimmunogenic and capable of long circulation even with repeated administration.[12] Antibody-based targeting is also being developed in conjunction with polymer systems. Similarly, ligand-based targeting using growth factors, hormones, vitamins (east.m., folate), peptides or other specific ligands is being pursued in conjunction with both liposomes and polymers. Liposomes are concentric bilayered structures made of amphipathic phospholipids and depending on the number of bilayer, liposomes are classified as multilamellar (MLV), small unilamellar (SUVs), or large unilamellar (LUVs). They range in size from 0.025-ten μ in diameter. The size and morphology of liposomes are regulated by the method of preparation and composition. Liposomes are used for delivery of drugs, vaccines, and genes for a multifariousness of disorders.[xiii]
Infectious diseases
Bacchawat and co-workers developed liposomal amphotericin and investigated it in brute models of fungal infection and leishmaniasis. Kshirsagar and co-workers modified the formulation, adult a "Patient Worthy" sterile pyrogen free liposomal amphotericin preparation and investigated it in patients with systemic fungal infections and leishmaniasis. It was found to exist safe producing significantly less adverse effects compared to plainly amphotericin in patients with systemic fungal infection, did not produce nephrotoxicity and could exist given to patients with renal damage. It was effective in patients resistant to fluconazole and plain amphotericin. Unlike Ambisome (USA), which needs to be used in dose of three mg/kg/twenty-four hours this is effective at 1 mg/kg/24-hour interval dose. The same group studied different dosage regimens of liposomal amphotericin using Aspergillus murine mode. Information technology was found that liposomal amphotericin was more than constructive than equal dose of gratuitous amphotericin B given after fungal spore claiming. A large single dose of liposomal amphotericin was more constructive, whether given before or later on spore challenge, than given equally two divided doses.[14] Information technology was investigated in patients with visceral leishmaniasis and constitute to exist effective in patients who had not responded to antimony, pentamidine, and amphotericin. Because of its safety, information technology tin can be given at iii mg/kg/day dose thus reducing full elapsing of handling. Information technology was successfully used in a child suffering from visceral leishmaniasis. This is the start liposomal grooming developed exterior of Us, which has been used in patients. In an attempt to improve efficacy and reduce toxicity further, liposomes with grafted ligand take been developed. Pentamidine isethionate and its methoxy derivative were encapsulated in sugar grafted liposomes and tested against experimental leishmaniasis in vivo. Information technology was seen that sugar grafted liposomes specially the mannose grafted ones were potent in comparing to normal liposome encapsulated drug or free drug.[15]
Anticancer drugs
Anticancer drugs provide current information on the clinical and experimental effects of toxic and non-toxic cancer agents and is specifically directed towards breakthroughs in cancer treatment. Mukhopadhya developed cohabit of antineoplastic drug daunomycin (DNM) with maleylated bovine serum albumin. Information technology was taken up with high efficiency by multi drug resistant variant JD100 of the murine-macrophage tumor jail cell line J774A.1 through the scavenger receptors resulting in cessation of DNA synthesis. A thermosensitive liposomal taxol formulation (rut mediated targeted drug delivery) in murine melanoma was developed and studied by another group of workers. Cremophor which is used as excipient due to the depression aqueous solubility of taxol has toxic side furnishings. Temperature-sensitive liposomes encapsulating taxol were prepared using egg phosphatidylcholine and cholesterol in combination with ethanol. The liposomes accept a phase transition temperature of 43°C.[16] A pregnant reduction in tumor volume was noted in tumor bearing mice treated with a combination of hyperthermia and theromosensitive liposome encapsulated taxol, compared to animals treated with free taxol with or without hyperthermia in B16F 10 murine melanoma transplanted into C57BI/6 mice. Sharma et al. besides investigated the use of polyvinylpyrrolidone nanoparticles containing taxol prepared by reverse micro-emulsion method. The size of nanoparticle was institute to exist 50-60 nm. The antitumor result of taxol was evaluated in B16F10 murine melanoma transplanted in C57 B 1/vi mice. in vivo efficacy of taxol containing nanoparticles as measured by reduction in tumor volume and increased survival fourth dimension was significantly greater than that of an equivalent concentration of free taxol.[17]
Lung-specific drug delivery
Pulmonary drug delivery offers several advantages in the treatment of respiratory diseases over other routes of administration. Inhalation therapy enables the direct application of a drug within the lungs. The local pulmonary degradation and delivery of the administered drug facilitates a targeted handling of respiratory diseases, such as pulmonary arterial hypertension (PAH), without the need for high dose exposures by other routes of administration. The intravenous application of brusque acting vasodilators has been the therapy of choice for patients with PAH over the past decade. The relative severity of side furnishings led to the development of newprostacyclin analogues and alternative routes of administration. 1 such analogue, iloprost (Ventavis®), is a worldwide canonical therapeutic agent for treatment of PAH. Inhalation of this compound is an bonny concept minimizing the side effects by its pulmonary selectivity. Unfortunately, the short one-half-life of iloprost requires frequent inhalation manoeuvres, ranging up to 9 times a 24-hour interval. Therefore, an aerosolizable controlled release formulation would meliorate a patient's convenience and compliance. Controlled drug commitment systems take become increasingly attractive options for inhalation therapies. A big number of carrier systems accept been adult and investigated as potential controlled drug delivery formulations to the lung, including drug loaded lipid and polymer based particles. The apply of colloidal carrier systems for pulmonary drug delivery is an emerging field of interest in nanomedicine. The objective of this written report was to compare the pulmonary absorption and distribution characteristics of the hydrophilic model drug 5(vi)-carboxyfluorescein (CF) afterward aerosolization as solution or entrapped into nanoparticles in an isolated rabbit lung model (IPL). CF-nanoparticles were prepared from a new course of biocompatible, fast degrading, branched polyesters by a modified solvent displacement method. Physicochemical properties, morphology, encapsulation efficiency, in vitro drug release, stability of nanoparticles to nebulization, aerosol characteristics as well as pulmonary dye absorption and distribution profiles after nebulization in an IPL were investigated Amidst the various drug delivery systems considered for pulmonary application, nanoparticles demonstrate several advantages for the treatment of respiratory diseases, such as prolonged drug release, jail cell-specific targeted drug commitment or modified biological distribution of drugs, both at the cellular and organ level. It must first be recognized that formulating compounds and delivering them as aerosols is circuitous. Non only does information technology involve the conception of a stable solution or interruption in a medium (propellant) that is non also characterized as other systems, but the resultant organisation is also field of study to operation limitations. In order to efficiently reach the lung, the formulation must be atomized into particles having aerodynamic sizes between approximately 1 and five μ. Due to these particle size constraints, also equally inhalation toxicology concerns, the range of possible excipients to cull from during the formulation phase is substantially reduced. Additionally, limiting the concentration of excipients in a formulation is crucial for maintaining adequate aerosol performance. Thus, given the complexity of this relationship, formulating aerosols is a challenging endeavor. Although complex, the successful formulation of drugs for pulmonary commitment provides a valuable therapeutic route. Upon introduction of the metered dose inhaler (MDI), medical treatment of lung diseases changed significantly. Since that fourth dimension, MDIs have become the virtually effective ways of controlling symptoms of lung diseases such as asthma and chronic obstructive pulmonary disorder (COPD). More recently, conception modifications were merited when cfc (CFC) propellants were linked to the depletion of the ozone layer (Molina and Rowland, 1974). With the successful transition to new propellant systems, MDIs are all the same well accustomed and highly utilized by patients across the globe today. Looking forward, the effectiveness, ease of apply, and relatively depression cost of droplets preparations in combination with modifications in delivery technology and conception sciences, will likely expand the handling of diseases. Some other, therapeutically undesirable attribute of pulmonary drug commitment is rapid absorption of almost drugs from the lung, necessitating frequent dosing, eastward.g., of bronchodilators and corticosteroids. Liposomes are believed to convalesce some of the problems encountered with conventional aerosol delivery due to their power to: (i) serve every bit a solubilization matrix for poorly soluble agents; (ii) deed as a pulmonary sustained release reservoir; and (iii) facilitate intracellular delivery of[18]
Targeting to brain
The great interest in mucosal vaccine delivery arises from the fact that mucosal surfaces represent the major site of entry for many pathogens. Among other mucosal sites, nasal delivery is especially bonny for immunization, as the nasal epithelium is characterized by relatively high permeability, low enzymatic activity and by the presence of an important number of immunocompetent cells. In addition to these advantageous characteristics, the nasal route could offer simplified and more cost-effective protocols for vaccination with improved patient compliance. The use of nanocarriers provides a suitable mode for the nasal delivery of antigenic molecules. Besides improved protection and facilitated transport of the antigen, nanoparticulate commitment systems could also provide more constructive antigen recognition by immune cells. These stand for fundamental factors in the optimal processing and presentation of the antigen, and therefore in the subsequent evolution of a suitable immune response. In this sense, the design of optimized vaccine nanocarriers offers a promising mode for nasal mucosal vaccination.[21]
The usual noninvasive arroyo to solving the brain drug delivery problem istolipidizethe drug, The water -soluble parts of the drugs restricts BBB transport conversion of h2o-soluble drug into lipid-soluble prodrug is the traditional chemical science driven solution to the BBB trouble equally in [Figure one].
Outline of a program for developing blood-encephalon drug targeting strategies derived from either chemical science based or biology-based disciplines
The treatment of CNS diseases is particularly challenging considering the commitment of drug molecules to the brain is ofttimes precluded by a variety of physiological, metabolic and biochemical obstacles that collectively comprise the Blood Encephalon bulwark, blood cerebrospinal fluid bulwark, Blood tumor bulwark. The present outlook for patients suffering from many types of brain diseases remains poor, merely recent developments in drug delivery techniques provide reasonable hope that the formidable barriers shielding the brain may ultimately be overcome. Drug delivery direct to the encephalon interstitium has recently been markedly enhanced through the rational design of polymer-based drug delivery systems. Substantial progress volition only come about, however, if continued vigorous inquiry efforts to develop more therapeutic and less toxic drug molecules are paralleled by the ambitious pursuit of more effective mechanisms for delivering those drugs to encephalon targets.[19] Jain et al. developed dopamine hydrochloride bearing positively charged small liposomes by sonicating multilamellar vesicles and studied their physical attributes and drug leakage and release design. In vivo performance was assessed by periodic measurement of chlorpromazine induced catatonia in Sprague Dawley rats and was compared with manifestly dopamine hydrochloride, dopamine and levodopa carbidopa. The studies showed that dopamine can be effectively delivered into the brain and its degradation in circulation can be prevented past incorporating information technology into liposomes.[20]
Strategies for drug commitment to the brain
Several drugs practice non accept acceptable physiochemical characteristics such equally high lipid solubility, low molecular size and positive charge which are essential to succeed in traversing BBB.[21]
Disruption of the BBB
The thought behind this approach was to interruption downward the barrier momentarily past injecting mannitol solution into arteries in the neck. The resulting high sugar concentration in brain capillaries takes up water out of the endothelial cells, shrinking them, thus opening tight junction. The effect lasts for 20-thirty infinitesimal, during which fourth dimension drugs diffuse freely, that would not normally cross the BBB. This method permitted the delivery of chemotherapeutic agents in patients with cognitive lymphoma, cancerous glioma and disseminated CNS germ cell tumors. Physiological stress, transient increase in intracranial force per unit area, and unwanted delivery of anticancer agents to normal encephalon tissues are the undesired side-effects of this approach in humans.[10]
Intraventricular/intrathecaldelivery
Hither, using a plastic reservoir, which implanted subcutaneously in the scalp and continued to the ventricles within the brain by an outlet catheter. Drug injection into the CSF is a suitable strategy for sites close to the ventricles only.[22]
Intra nasal drug commitment
Afterward nasal delivery drugs first attain the respiratory epithelium, where compounds can exist captivated into the systemic circulation past tran cellular and para cellular passive assimilation, carrier-mediated send, and absorption through trancytosis. When a nasal drug formulation is delivered deep and loftier enough into the nasal cavity, the olfactory mucosa may be reached and drug transport into the brain and/or CSF via the olfactory receptor neurons may occur.[23]
Possible systems for drug delivery-colloidal drug carriers
Colloidal drug carrier systems such as micellar solutions, vesicle and liquid crystal dispersions, likewise as nanoparticle dispersions consisting of small particles show great promise equally drug delivery systems. The goal is to obtain systems with optimized drug loading and release backdrop, long shelf-life and low toxicity. The incorporated drug participates in the microstructure of the system, and may fifty-fifty influence it due to molecular interactions, especially if the drug possesses amphiphilic and/or mesogenic properties.[24]
Micelles
Micelles formed by self-assembly of amphiphilic cake copolymers (5-50 nm) in aqueous solutions are of peachy interest for drug delivery applications. The drugs tin can be physically entrapped in the cadre of cake copolymer micelles and transported at concentrations that can exceed their intrinsic h2o- solubility. Moreover, the hydrophilic blocks tin can form hydrogen bonds with the aqueous surroundings and form a tight shell effectually the micellar core. As a result, the contents of the hydrophobic core are finer protected against hydrolysis and enzymatic degradation. In improver, the corona may prevent recognition by the reticuloendothelial arrangement and therefore preliminary elimination of the micelles from the bloodstream. The fact that their chemic composition, total molecular weight and block length ratios tin can exist easily changed, which allows command of the size and morphology of the micelles. Functionalization of cake copolymers with cross linkable groups tin can increase the stability of the corresponding micelles and improve their temporal command.[25]
Liposomes
Liposomes were kickoff produced in England in 1961 by Alec D. Bangham. Ane finish of each molecule is water soluble, while the contrary cease is h2o insoluble. Water-soluble medications added to the water were trapped within the assemblage of the hydrophobic ends; fatty-soluble medications were incorporated into the phospholipid layer as in [Figure ii].
Liposomes, micelles, bilayer sheet
In some cases liposomes attach to cellular membranes and announced to fuse with them, releasing their or drugs into the cell. In the case of phagocytic cells, the liposomes are taken upward, the phospholipid walls are acted upon past organelles called lysosomes, and the medication is released. Liposomal delivery systems are still largely experimental; the precise mechanisms of their action in the body are under study, every bit are means in which to target them to specific diseased tissues.[26]
Nano engineering science
Nanoparticulate systems for brain delivery of drugs
I of the possibilities to deliver drugs to the brain is the employment of nanoparticles. Nanopartiacles are polymeric particles fabricated of natural or artificial polymers ranging in size between nigh 10 and 1000 nm (1 mm). Drugs may exist bound inform of a solid solution or dispersion or exist adsorbed to the surface or chemically attached. Poly (butylcyanoacrylate) nanoparticles stand for the onlynanoparticles that were and then far successfully used for the in vivo commitment of drugs to the brain. The first drug that was de-livered to the brain using nanoparticles was the hexapeptidedalargin (Tyr-D-Ala- Gly- Phe-Leu-Arg), a Leu-enkephalin analogue with opioid activeness.[27]
Nanoparticles and nanoformulations have already been applied as drug commitment systems with bully success; and nanoparticulate drug delivery systems have still greater potential for many applications, including anti-tumors therapy, cistron therapy, and AIDS therapy, radiotherapy, in the delivery of proteins, antibiotics, virostatics, and vaccines and as vesicles to laissez passer the blood-brain barrier.[28]
Nanoparticles provide massive advantages regarding drug targeting, delivery and release, and with their additional potential to combine diagnosis and therapy, emerge equally one of the major tools in nanomedicine. The main goals are to improve their stability in the biological environment, to mediate the bio-distribution of agile compounds, meliorate drug loading, targeting, transport, release, and interaction with biological barriers. The cytotoxicity of nanoparticles or their degradation products remains a major problem, and improvements in biocompatibility obviously are a master business organization of future research.[29,30]
Nowadays nanotechnology is proved to be more than efficient for enhancing drug commitment to brain. The nanoparticles are the drug carrier system which is fabricated from a broad number of materials such as poly (alkylcyanoacrylates) (pacas),polyacetates, polysaccharides, and copolymers. The methods of preparation of nanoparticles, their characterization and medical application have been reviewed in detail.[31] The exact mechanism of nanoparticle transport into encephalon is not understood, but information technology is thought to depend on the particles size, material composition, and construction. In some cases it is reported to mimic molecules that would commonly be transported to brain. For example, polysorbate-coated nanoparticles are idea to mimic low-density lipoprotein (LDL), assuasive them to be transported across the capillary wall and into the encephalon past hitching a ride on the LDL receptor.[32]
The nanotechnology includes:
-
Coated nanoparticles
-
Pegylated nanoparticles
-
Solid Lipid nanoparticles (SLN)
-
Nanogels
Transdermal delivery
Bioadhesive liposomes bearing levonorgestrel every bit controlled drug commitment system has been studied.[26] Mesophasic proliposomal arrangement for levonorgestral was prepared. The vesicles were mostly unilamellar and some were multilamellar. Release was of zero order kinetics. Booze as compared to oils had greater effect on transdermal flux. In vivo studies showed that a significant lag phase was observed before the therapeutic levels were reached indicating the requirement for a loading dose. This proliposomes system was institute to be superior to PEG-based ointment system. Liposomal reservoir system bearing local anesthetic benzocaine was developed[33] for controlled and localized commitment via topical route. The liposomal interruption was incorporated into an ointment and gel base. The systems delivered the drug at a controlled rate ever 24 hr compared to plain ointment which had a apace decreased release rate. The drug delivery across human cadaver skin was very slow. In vivo studies showed a longer duration of action in the case of liposomal conception.[34]
Miscellaneous
Nabar studied the consequence of size and accuse of liposome in the bio-distribution of 99m TC-DTPA encapsulated in liposome after intravenous injection in rats. They observed that multilamellar vesicles (MLV) were taken up to a greater extent as compared to SUVs in liver spleen and lungs. Positively charged MLVs than negative or neutral ones, were taken up more in liver, positively charged SUVs were taken up more than in kidneys and neutral MLVs were taken upward more than in lungs than charged ones.[35] An endeavour was made to improve stability of liposome by coupling the drug with the lipid bilayer using a cross linking agent.[36] Soya phosphatidylcholine (SPC) containing liposomes were prepared by calcium induced fusion method. Positively charged stearylamine was introduced in the bilayer. The liposomes were coupled to entrapped ibuprofen by EDAC (ane-ethyl 3-(3-dimethyl aminopropyl) carbodiimide HCI) and the coupling was confirmed past UV spectrum. It was observed that EDAC in SPC containing stearylamine liposomes retarded the release of ibuprofen significantly. In albino rats, the various factors affecting systemic absorption of nasally practical gentamycin sulphate using in situ nasal perfusion technique was studied.[37] Tween 80 which is a surfactant increases permeation by altering membrane construction and permeability. In this study Tween 80 upto 1% w/v concentrations, increased permeability. Betacyclodextrin at 0.25% due west/five concentration, another permeability enhancer was constitute to significantly increase permeability initially but was found to plateau off later on on. However, both these permeability enhancer were found to decrease stability and authority of gentamycin.[38]
OTHER CONTROLLED DRUG DELIVERY SYSTEMS
Extended release, slow release and sustained release preparation have been developed by pharmaceutical industry and pharmacy departments and investigated in vitro for release pattern and in vivo for bio-equivalence.[39]
Oral
There is a dandy need in oral delivery of protein and peptide drugs, suitable devices for delivering the therapeutic amanuensis incorporated microspheres selectively in the intestine. Gelatin capsules were coated with various concentrations of sodium alginate and cross-linked with appropriate concentrations of calcium chloride and tested in vitro for resistance to gastric and abdominal medium. Gelatin capsules coated with 20% westward/five of the polymer, which gave the about promising effect in vitro, were evaluated in man volunteers for their in vivo gastro intestinal tract behaviour. The radiographical studies prove that while the un-coated gelatin capsules disintegrated in the stomach within 15 min of ingestion, the alginate-coated gelatin capsules remained intact as long as they were retained in the breadbasket (up to 3 h) and and then migrated to the ileocecal region of the intestine and disintegrated.[40–43] Vanarase and Nagarsenkar prepared pellets of ane mm and 1.65 mm size of prochlorperazine maleate using a modern pelletization technique. The pellets were coated with ethylcellulose and evaluated for in vitro release, using USP dissolution apparatus. They noted that release of PCPM tin can be reduced with increasing amount of ethylcellulose.[44–46] Rangaiah et al. prepared and studied the sustained release tablets of theophylline using Eudragit RL, RS, and Hydroxy propyl methyl cellulose. Bioavailability studies in volunteers showed that HPMC and Eudragit formulation produced sustained plasma concentration of the drug. Another grouping 35 formulated sustained release capsules of nifedipine containing an initial rapidly available loading dose in the form of solid dispersion and a sustained release role as micro particles coated with polyvinyl acetate (Thou.wt 45,000) film using a modified Wurster coating apparatus.[47] The products provided release of initial therapeutic dose of drug in less than 45 min and sustained release over 11-12 hours. The same group adult a diffusion prison cell for the conclusion of drug release from a topical aerosol formulation.[48]
Parenteral
Kushwaha used a blend of synthetic polymer polyvinyl booze and natural macromolecule gum Arabica and found that duration and release of drug depends on the amount of drug loaded in the matrix and solubility of the drug in the matrix and the release medium. The advantage of this system is that the release kinetics of the drug from the system can exist tailored by adjusting the plasticizer, homopolymer and cross linker composition. Chitosan microspheres of 45-300 μ were used for controlled commitment of progesterone.[49] In vitro and in vivo release was tested. Information technology was seen that highly cross linked spheres released only 35% of incorporated steroids in 40 days compared to lxx% from lightly cross linked spheres. Decision of in vivo bioavailability of the steroid from microsphere formulation by intramuscular injection in rabbits showed that a plasma concentration of 1-2 μg/ ml was maintained upto 5 months without a high outburst event. The data suggests that cross linked chitosan microspheres would be an interesting organization for long term commitment of steroids. Cross linked dextran chaplet were adult equally a carrier for development of a single contact vaccine delivery arrangement.[l–54] There has been extensive inquiry on drug delivery by biodegradable polymeric devices since bioresorbable surgical sutures entered the marketplace two decades agone. Amongst the different classes of biodegradable polymers, the thermoplastic aliphatic poly (esters) such as poly (lactide) (PLA), poly (glycolide) (PGA), and especially the copolymer of lactide and glycolide referred to as poly (lactide-co-glycolide) (PLGA) accept generated tremendous interest because of their excellent bio-compatibility, biodegradability, and mechanical strength.[55] They are easy to formulate into various devices for conveying a variety of drug classes such every bit vaccines, peptides, proteins, and micromolecules. Near importantly, they have been canonical by the United States Food and Drug.
Administration (FDA) for drug delivery. Dhiman and Khuller[56,57,58,59] institute that mice immunized with microparticles of poly (DL-lactide-co-glycolide) (DLPLG) as delivery vehicles for 71-KDa prison cell wall associated protein of mycobacterium tuberculosis H37 Ra, exhibited significantly higher T cell stimulation and cytokine release in comparison to 71-KDa emulsified in Freund'south incomplete adjuvant (FIA) as well equally BCG vaccinated group. Further, the protective effect of 71KDa- PLG was compared with 71-KDa FIA on the basis of survival rates and viable bacilli load in dissimilar organs at 30 days mail claiming and median lethal dose (LCD50) of Mycobacterium tuberculosis H37Rv. The 71-KDa PLG was more constructive when claiming was given 16 calendar week later on immunization. Further, 71KaDa- PLG immunized group exhibited a significantly higher clearance of bacterial load from the lungs and livers in comparison to the 71KDa FIA immunized group. Poly (lactide-co-glycolide) (PLG) was used to deliver diclofenac in the form of microspheres and in situ gel-forming systems, subcutaneously. The pharmacokinetic and pharmacodynamics studies in the adjuvant - induced arthritic rats showed that microspheres produced steady therapeutic levels of the drug in the plasma for almost 16 days following a single subcutaneous injection. The in situ gel-forming provided significantly college maximum plasma concentration and inhibition of inflammation was maintained for nearly 10 days.[60–63]
Dental production
Somayaji et al. used an ethylcellulose strip as commitment medium for tetracycline and metronidazole to reduce sub-gingival microorganisms in periodontal pockets. Patients were given supragingival scaling and so divided into 5 groups, depending on the length of time the medication was in place. Sites were marked for tetracycline, metronidazole, and placebo. Sites were wiped and isolated, and baseline microbiology samples were taken for gram staining and culture methods.[64] After handling, subgingival microbiological samples were taken again. The ethyl cellulose strips were removed and analyzed for any remaining drug. Results showed that tetracycline and metronidazole could both be applied locally to periodontal sites using ethyl cellulose strips and markedly supress the subgingival bacteria over a period of several days. The tetracycline showed a faster release; however, the metronidazole required a lesser concentration to reach consummate reduction of the subgingival flora. A saliva activated bio-adhesive drug delivery organisation was adult[65] for lidocaine hydrochloride and compared its effect with topical gel preparation in dentistry. It was found that DDS adhered to gingival within a minute and produced meridian issue in 15 minutes and produced greater depth of anesthesia than the marketed topical gel.
Colon-specific drug delivery
The increasing number of peptide and protein drugs being investigated demands the development of dosage forms which exhibit site-specific release. Delivery of drugs into systemic circulation through colonic assimilation represents a novel mode of introducing peptide and protein drug molecules and drugs that are poorly absorbed from the upper gastrointestinal (GI) tract.[66] Oral colon-specific drug delivery systems offering obvious advantages over parenteral administration. Colon targeting is naturally of value for the topical treatment of diseases of the colon such every bit Crohn's disease, ulcerative colitis and colorectal cancer. Sustained colonic release of drugs can be useful in the handling of nocturnal asthma, angina and arthritis. Peptides, proteins, oligonucleotides, and vaccines are the potential candidates of interest for colon-specific drug delivery. Sulfasalazine, ipsalazide, and olsalazine accept been adult as colon-specific delivery systems for the treatment of inflammatory bowel illness (IBD).[65] The vast microflora and distinct enzymes nowadays in the colon are being increasingly exploited to release drugs in the colon. Although the large intestine is a potential site for absorption of drugs, some difficulties are involved in the constructive local delivery of drugs to the colon bypassing the stomach and small intestine.[67] Furthermore, differential pH conditions and long transit time during the passage of drug formulations from mouth to colon create numerous technical difficulties in the safe delivery of drugs to the colon. However, contempo developments in pharmaceutical engineering, including coating drugs with pH-sensitive and bacterial degradable polymers, embedding in bacterial degradable matrices and designing into prodrugs, have provided renewed hope to effectively target drugs to the colon. The employ of pH changes is analogous to the more common enteric coating and consists of employing a polymer with an advisable pH solubility profile. The concept of using pH as a trigger to release a drug in the colon is based on the pH conditions that vary continuously down the GI tract.[68] Polysaccharide and azopolymer coating, which is refractory in the stomach and modest intestine yet degraded past the colonic bacteria, accept been used as carriers for colon-specific targeting. Finally, the availability of optimal preclinical models and clinical methods fueled the rapid development and evaluation of colon-specific drug delivery systems for clinical use. Hereafter studies may hopefully pb to further refinements in the technology of colon-specific drug delivery systems and ameliorate the pharmacotherapy of peptide drugs.[69]
The necessity and advantages of colon-specific drug commitment systems have been well recognized and documented.[70] In the past, the primary approaches to obtain colon-specific delivery accomplished limited success and included prodrugs, pH- and time-dependent systems, and microflora-activated systems. Precise colon drug delivery requires that the triggering mechanism in the delivery system only respond to the physiological conditions particular to the colon. Hence, continuous efforts have been focused on designing colon-specific delivery systems with improved site specificity and versatile drug release kinetics to adapt unlike therapeutic needs.[71]
Amidst the systems developed most recently for colon-specific delivery, four systems were unique in terms of achieving in vivo site specificity, pattern rationale, and feasibility of the manufacturing procedure (pressure-controlled colon delivery capsules (PCDCs), CODES, colonic drug delivery system based on pectin and galactomannan coating, and Azo hydrogels). The focus of this review is to provide detailed descriptions of the iv systems, in item, and in vitro/in vivo evaluation of colon-specific drug delivery systems, in general. Specific targeting of drugs to the colon is recognized to have several therapeutic advantages.[72] Drugs, which are destroyed by the stomach acid and/or metabolized past pancreatic enzymes, are slightly affected in the colon, and sustained colonic release of drugs can exist useful in the treatment of nocturnal asthma, angina and arthritis. Treatment of colonic diseases such equally ulcerative colitis, colorectal cancer and Crohn'southward affliction is more than constructive with directly commitment of drugs to the affected area. Likewise, colonic delivery of vermicides and colonic diagnostic agents require smaller doses. Prasad et al. developed a colon-specific oral tablet using guar gum equally carrier.[73]
Colonic drug commitment has gained increased importance not but for the delivery of the drugs for the treatment of local diseases associated with the colon but also for its potential for the delivery of proteins and therapeutic peptides.[74] To reach successful colonic delivery, a drug needs to be protected from absorption and/or the environment of the upper gastrointestinal tract (GIT) and and so be abruptly released into the proximal colon, which is considered the optimum site for colon-targeted delivery of drugs. Colon targeting is naturally of value for the topical treatment of diseases of colon such as Chron'south diseases, ulcerative colitis, colorectal cancer and amebiasis. Peptides, proteins, oligonucleotides, and vaccines pose potential candidature for colon targeted drug delivery.[75]
Drug release studies under conditions mimicking mouth to colon transit accept showed that guar mucilage protects the drug from beingness released completely in the physiological environment of stomach and small intestine. Guar gum at pH. 6.8 is susceptible to colonic bacterial enzyme action, with drug release. Pre-treatment of rats orally with aqueous dispersion of guar glue for iii days, induced enzyme specifically acting on guar gum,[76] thereby increasing drug release. The event indicates usefulness of guar gum as a potential carrier for colon specific drug delivery. A novel colon-specific drug delivery organization based on a polysaccharide, guar gum was evaluated in salubrious human male volunteers, with gamma scintigraphic study using technetium 99m-DTPA equally tracer. Information technology was seen that some amount of tracer present on the surface of the tablets was released in tum and small intestine and the bulk of the tracer present in the tablet mass was delivered to the colon. The colonic inflow fourth dimension of the tablets was 2-4 hr. On entering the colon, the tablets were found to degrade. In vitro release studies of the incorporated 5-flurouracil was carried out in faux gastric and intestinal fluids. In vitro release contour in presence of azoreductase in the culture of intestinal flora followed a cypher order pattern.[77]
Decision
Pharmaceutical development of drug delivery system is beingness pursued enthusiastically in many laboratories in India. These are being investigated in vitro for release blueprint and in some cases in vivo in animals for pharmacokinetics but less frequently for efficacy. There is a paucity of data on clinical studies and utility of the DDS in patients. It is necessary that pharmacologists should be involved in the investigation of pharmacokinetics and pharmacodynamics of DDS if the products have reached their meaningful event - the clinical use.
Footnotes
Source of Back up: Nada
Disharmonize of Involvement: None alleged.
REFERENCES
1. Panchagnula R. Transdermal delivery of drugs. Indian J Pharmacol. 1997;29:140–56. [Google Scholar]
two. Rao PR, Diwan PV. Conception and in vitro evaluation of polymeric films of diltiazem hydrochloride and indomethacin for transdermal administration. Drug Dev Indian Pharm. 1998;24:327–36. [PubMed] [Google Scholar]
3. Rao PR, Diwan PV. Permeability studies of cellulose acetate free films for transdermal use: Influence of plasticizers. Pharm Acta Helv. 1997;72:47–51. [PubMed] [Google Scholar]
4. Thacharodi D, Rap KP. Evolution and in vitro evaluation of chitosan-based trandermal drug delivery organization for the controlled delivery of propranolol hydrochloride. Biomaterials. 1995;sixteen:145–8. [PubMed] [Google Scholar]
5. Krishna R, Pandit JK. Carboxymethylcellulose-sodium based transdermal drug delivery system for propranolol. J Pharm Pharmacol. 1996;48:367–70. [PubMed] [Google Scholar]
6. Bhat M, Shenoy DS, Udupa Northward, Srinivas CR. Optimization of delivery of betamethasone - dipropionate from skin preparation. Indian Drugs. 1995;32:211–4. [Google Scholar]
7. Misra A, Pal R, Majumdar SS, Talwar GP, Singh O. Biphasic testosterone delivery profile observed with two unlike transdermal formulations. Pharm Res. 1997;xiv:1264–8. [PubMed] [Google Scholar]
viii. Thacharodi D, Rao KP. Rate-controlling biopolymer membranes every bit transdermal delivery systems for nifedipine: Development and in vitro evaluations. Biomaterials. 1996;17:1307–xi. [PubMed] [Google Scholar]
nine. Nanda A, Khar RK. Permeability characteristics of complimentary films were studied using the drugs such as diltiazem hydrochloride and indomethacin. Drug Dev Indian Pharm. 1994;twenty:3033–44. [Google Scholar]
10. Mukhopadhyay A, Mukhopadhyay B, Basu K. Circumvention of multidrug resistance in neoplastic cells through scavenger receptor mediated drug delivery. FEBS Lett. 1995;276:95–8. [PubMed] [Google Scholar]
11. Nanda A, Khar RK. Pulsed mode constant current iontophonetic transdermal delivery of propranalol hydrochloride in astute hypertensive and normotensive rats. Indian Drugs. 1998;35:274–lxxx. [Google Scholar]
12. Murthy SN, Shobha Rani HS. Comparative pharmacokinetic and pharmacodynamic evaluation of oral vs transdermal delivery of terbutaline sulphate. Indian Drugs. 1998;35:34–half-dozen. [Google Scholar]
xiii. Rao MY, Vani G, Chary BR. Design and evaluation of mucoadhesive drug commitment systems. Indian Drugs. 1998;35:558–65. [Google Scholar]
14. Murthy NS, Satheesh K. Enhancer synergism of propylene glycol and PEG -400 in terbutaline sulphate transdermal drug commitment systems. Indian Drugs. 1997;34:224–half-dozen. [Google Scholar]
15. Tatapudy H, Madan PL. Benzoyl peroxide microcapsules I.training of core material. Indian Drugs. 1995;32:239–48. [Google Scholar]
xvi. Kshirsagar NA, Gokhale PC, Pandya SK. Liposomes as drug delivery system in leishmaniasis. J Assoc Physicians India. 1995;43:46–8. [PubMed] [Google Scholar]
17. Kshirasagar NA, Bodhe PV, Kotwani RN. Targeted drug delivery in visceral leishmaniasis. J Par Dis. 1997;21:21–4. [Google Scholar]
xviii. Kotwani RN, Gokhale PC, Kshirsagar NA, Pandya SK. Optimizing dosage regimens of liposomal amphotericin B using Aspergillus murine model. Indian J Pharmacol. 1996;28:88–92. [Google Scholar]
19. Gokhale PC, Kshirsagar NA, Khan MU, Pandya SK, Meisheri YV, Thakur CP, et al. Successful treatment of resistant visceral leishmaniasis with liposomal amphotericin B. Trans Roy Soc Trop Med Hyg. 1994;88:228. [PubMed] [Google Scholar]
twenty. Karande SC, John Boby KF, Lahiri KR, Jain MK, Kshirsagar NA, Gokhale PC, et al. Successful handling of antimony - resistant visceral leishmaniasis with liposomal amphotericin B (L-amp-LRC) in child. Trop Doct. 1995;25:80–1. [PubMed] [Google Scholar]
21. Banerjee G, Nandi K, Mahato SB, Pakrashi A, Basu MK. Drug delivery organisation: Targeting of pentamidines to specific sites using sugar grafted liposomes. J Antimicrob Chemother. 1996;38:145–l. [PubMed] [Google Scholar]
22. Sharma D, Chelvi TP, Kaur J, Ralhan R. Thermosensitive liposomal taxol formulation: Rut-mediated targeted drug delivery in murine melanoma. Melanoma Res. 1998;eight:240–4. [PubMed] [Google Scholar]
23. Sharma D, Chelvi TP, Kaur J, Chakravorty K, De TK, Maitra A, et al. Novel taxol formulation: Polyvinylpyrrolidone nanoparticle-encapsulated taxol for drug commitment in cancer therapy. Oncol Res. 1996;8:281–6. [PubMed] [Google Scholar]
24. Deol P, Khuller GK. Lung specific stealth liposomes: Stability, biodistribution and toxicity of liposomal antitubercular drugs in mice. Biochimica Biophysi Acta. 1997;1334:161–72. [PubMed] [Google Scholar]
25. Jain NK, Rana Air conditioning, Jain SK. Encephalon drug commitment system bearing dopamine hydrochloride for effective direction of parkinsonism. Drug Dev Ind Pharm. 1998;24:671–five. [PubMed] [Google Scholar]
26. Uppadhyay AK, Dixit VK. Bioadhesive liposomes bearing levonorgestrel as controlled drug commitment system. Pharmazie. 1998;53:421–2. [PubMed] [Google Scholar]
27. Deo Mr, Sant VP, Parekh SR, Khopade AJ, Banakar UV. Proliposome-based transdermal delivery of levonorgestrel. J Biomat App. 1997;12:77–88. [PubMed] [Google Scholar]
28. Singh R, Vyas SP. Topical liposomal system for localized and controlled drug delivery. J DermatoI Sci. 1996;13:107–11. [PubMed] [Google Scholar]
29. Nabar SJ, Nadkarni GD. Event of size and charge of liposomes on biodistribution of encapsulated 99mTc - DTPA in rats. Indian J Pharmacol. 1998;30:199–202. [Google Scholar]
30. Sivakumar PA, Mythily S, Alamelu South, Rao PK. Liposome - ibuprofen conjugate and the release characteristics of ibuprofen. Indian Drugs. 1994;31:568–73. [Google Scholar]
31. Martin DB, Udupa N. Nasal drug delivery of gentamycin sulphate. Indian Drugs. 1994;31:365–9. [Google Scholar]
32. Narayani R, Rao KP. Polymer-coated gelatin capsules equally oral delivery devices and their alimentary canal behavior in humans. J Biomater Sci Polym Ed. 1995;7:39–48. [PubMed] [Google Scholar]
33. Vanarase SY, Nagarsenkar MS. In-vitro release studies of prochlorperazine pellets coated with ethylcellulose. Indian Drugs. 1995;32:134–8. [Google Scholar]
34. Rangaiah KV, Madhusudhan S, Verma PR. Sustained release of theophylline from HPMC and Eudragit tablet. Indian Drugs. 1995;32:543–7. [Google Scholar]
35. Asgar A, Sharma SN. Sustained release through coated microparticles of nifedipine. Indian Drugs. 1996;33:30–v. [Google Scholar]
36. Asgar A, Radha S, Agarwal SP. Fabrication of a diffusion cell for the determination of drug release from topical droplets formulations. Indian Drugs. 1997;34:715–7. [Google Scholar]
37. Kushwaha V, Bhowmick A, Behera BK, Ray AR. Sustained release of antimicrobial drugs from polyvinylalcohol and mucilage arabica blend matrix. Art Cells Claret Subst Immobilization Biotechnol. 1998;26:159–72. [PubMed] [Google Scholar]
38. Jameela SR, Kumary TV, Lal AV, Jayakrishnan A. Progressive loaded chitosan microspheres: A long acting biodegradable controlled commitment system. J Cont Rel. 1998;52:17–24. [PubMed] [Google Scholar]
39. Diwan M, Misra A, Khar RK, Talwar GP. Long-term loftier immune response to diphtheria toxoid in rodents with diphtheria toxoid conjugated to dextran as a single contact point delivery system. Vaccine. 1997;15:1867–71. [PubMed] [Google Scholar]
40. Jain R, Shah NH, Malick AW, Rhodes CT. Controlled drug commitment by biodegradable poly (ester) devices: Unlike preparative approaches. Drug Dev Indian Pharm. 1998;24:703–27. [PubMed] [Google Scholar]
41. Dhiman N, Khuller GK. Protective efficacy of mycobacterial 71-KDa cell wall associated protein using poly (DLlactide- co-glycolide) microparticles equally carrier vehicles. FEMS Immunol Med Microbiol. 1998;21:nineteen–28. [PubMed] [Google Scholar]
42. Chandrashekar G, Udupa Northward. Biodegradable injectable implant systems for long term drug delivery using poly (lactic- co-glycolic) acid copolymers. J Pharm Pharmacol. 1996;48:669–74. [PubMed] [Google Scholar]
43. Somayaji BV, Jariwala U, Jayachandran P, Vidyalakshmi 1000, Dudhani RV. Evaluation of antimicrobial efficacy and release blueprint of tetracycline and metronidazole using a local delivery system. J Periodontol. 1998;69:409–13. [PubMed] [Google Scholar]
44. Taware CP, Mazumdar S, Pendharkar One thousand, Adani MH, Devarajan PV. A bioadhesive delivery system as an alternative to infiltration anesthesia. Oral Sur Oral Med Oral Pathol Oral Radiol Endodontics. 1997;84:609–15. [PubMed] [Google Scholar]
45. Prasad YV, Krishnaiah YS, Satyanarayana S. In vitro evaluation of guar gum as a carrier for colon-specific drug delivery. J Control Relaese. 1998;51:281–7. [PubMed] [Google Scholar]
46. Krishnaiah YS, Satyanarayana S, Rama Prasad YV, Narasimha Rao Due south. Gamma scintigraphic studies on guar gum matrix tablets for colonic drug delivery in healthy human volunteers. J Control Release. 1998;55:245–52. [PubMed] [Google Scholar]
47. Shantha KL, Ravichandran P, Rao KP. Azo polymeric hydrogels for colon targeted drug delivery. Biomaterials. 1995;16:1313–8. [PubMed] [Google Scholar]
48. Khuller GK, Kapur Thousand, Sharma Due south. Liposome applied science for drug delivery against mycobacterial infections. Curr Pharm Des. 2004;10:3263–74. [PubMed] [Google Scholar]
49. Bala I, Hariharan Due south, Kumar MN. PLGA nanoparticles in drug delivery: the state of the art. Crit Rev Ther Drug Carrier Syst. 2004;21:387–422. [PubMed] [Google Scholar]
50. Vauthier C, Dubernet C, Fattal E, Pinto-Alphandary H, Couvreur P. Poly(alkylcyanoacrylates) as biodegradable materials for biomedical applications. Adv Drug Deliv Rev. 2003;55:519–48. [PubMed] [Google Scholar]
51. Couvreur P, Barratt G, Fattal E, Legrand P, Vauthier C. Nanocapsule technology: A review. Crit Rev Ther Drug Carrier Syst. 2002;nineteen:99–134. [PubMed] [Google Scholar]
52. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski Nosotros. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release. 2001;70:1–xx. [PubMed] [Google Scholar]
53. Wissing SA, Kayser O, Muller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev. 2004;56:1257–72. [PubMed] [Google Scholar]
54. Florence AT. Issues in oral nanoparticle drug carrier uptake and targeting. J Drug Target. 2004;12:65–70. [PubMed] [Google Scholar]
55. Bummer PM. Physical chemical considerations of lipid-based oral drug delivery: Solid lipid nanoparticles. Crit Rev Ther Drug Carrier Syst. 2004;21:1–20. [PubMed] [Google Scholar]
56. Florence AT, Hussain Due north. Transcytosis of nanoparticle and dendrimer delivery systems: Evolving vistas. Adv Drug Deliv Rev. 2001;50:S69–89. [PubMed] [Google Scholar]
57. Pandey R, Zahoor A, Sharma Southward, Khuller GK. Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system confronting murine tuberculosis. Tuberculosis. 2003;83:373–8. [PubMed] [Google Scholar]
58. Sharma A, Pandey R, Sharma S, Khuller GK. Chemotherapeutic efficacy of poly (DL-lactide-co-glycolide) nanoparticle encapsulated antitubercular drugs at sub-therapeutic dose confronting experimental tuberculosis. Int J Antimicrob Agents. 2004;24:599–604. [PubMed] [Google Scholar]
59. Ain Q, Sharma S, Garg SK, Khuller GK. Role of poly [DL-lactide-co-glycolide] in development of a sustained oral delivery system for antitubercular drug(southward) Int J Pharm. 2002;239:37–46. [PubMed] [Google Scholar]
threescore. Dutt K, Khuller GK. Chemotherapy of Mycobacterium tuberculosis infections in mice with a combination of isoniazid and rifampicin entrapped in poly (DL-lactide-co-glycolide) microparticles. J Antimicrob Chemother. 2001;47:829–35. [PubMed] [Google Scholar]
61. Gabor F, Bogner E, Weissenboeck A, Wirth One thousand. The lectin-cell interaction and its implications to intestinal lectin-mediated drug delivery. Adv Drug Deliv Rev. 2004;56:459–80. [PubMed] [Google Scholar]
62. Sharma A, Sharma Due south, Khuller GK. Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. J Antimicrob Chemother. 2004;54:761–6. [PubMed] [Google Scholar]
63. Pandey R, Khuller GK. Antitubercular inhaled therapy: Opportunities, progress and challenges. J Antimicrob Chemother. 2005;55:430–5. [PubMed] [Google Scholar]
64. Pandey R, Sharma A, Zahoor A, Sharma South, Khuller GK, Prasad B. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug commitment organization for experimental tuberculosis. J Antimicrob Chemother. 2003;52:981–6. [PubMed] [Google Scholar]
65. Pandey R, Khuller GK. Solid lipid particle-based inhalable sustained drug commitment system against experimental tuberculosis. Tuberculosis (Edinb) 2005;85:227–34. [PubMed] [Google Scholar]
66. Pinto-Alphandary H, Andremont A, Couvreur P. Targeted delivery of antibiotics using liposomes and nanoparticles: Research and applications. Int J Antimicrob Agents. 2000;xiii:155–68. [PubMed] [Google Scholar]
67. Kayser O, Olbrich C, Croft SL, Kiderlen AF. Formulation and biopharmaceutical problems in the development of drug delivery systems for antiparasitic drugs. Parasitol Res. 2003;90:S63–70. [PubMed] [Google Scholar]
68. Anisimova YV, Gelperina SE, Peloquin CA, Heifets LB. Nanoparticles equally antituberculosis drugs carriers: effect on action against One thousand.tuberculosis in human monocyte-derived macrophages. J Nanoparticle Res. 2000;2:165–71. [Google Scholar]
69. Fawaz F, Bonini F, Maugein J, Lagueny AM. Ciprofloxacin-loaded polyisobutylcyanoacrylate nanoparticles: Pharmacokinetics and in vitro anti-microbial action. Int J Pharm. 1998;168:255–9. [Google Scholar]
70. Barrow EL, Winchester GA, Jay K, Staas JK, Quenelle DC, Barrow WW. Utilise of microsphere technology for targeted delivery of rifampin to Mycobacterium tuberculosis-infected macrophages. Antimicrob Agents Chemother. 1998;42:2682–9. [PMC gratis article] [PubMed] [Google Scholar]
71. Peters K, Leitzke Due south, Diederichs JE, Borner K, Hahn H, Muller RH, et al. Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. J Antimicrob Chemother. 2000;45:77–83. [PubMed] [Google Scholar]
72. Rabinow BE. Nanosuspensions in drug delivery. Nat Rev Drug Discov. 2004;3:785–96. [PubMed] [Google Scholar]
73. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: Theory to practice. Pharmacol Rev. 2001;53:283–318. [PubMed] [Google Scholar]
74. Pandey R, Khuller GK. Subcutaneous nanoparticle-based antitubercular chemotherapy in an experimental model. J Antimicrob Chemother. 2004;54:266–8. [PubMed] [Google Scholar]
75. Schmidt C, Bodmeier R. Incorporation of polymeric nanoparticles into solid dosage forms. J Command Release. 1999;57:115–25. [PubMed] [Google Scholar]
76. Sham JO, Zhang Y, Finlay WH, Roa WH, Lobenberg R. Formulation and label of spray-stale powders containing nanoparticles for aerosol commitment to the lung. Int J Pharm. 2004;269:457–67. [PubMed] [Google Scholar]
77. Tsapis N, Bennett D, Jackson B, Weitz DA, Edwards DA. Trojan particles: Big porous carriers of nanoparticles for drug delivery. Proc Natl Acad Sci. 2002;99:12001–5. [PMC free commodity] [PubMed] [Google Scholar]
Articles from International Journal of Pharmaceutical Investigation are provided here courtesy of Wolters Kluwer -- Medknow Publications
Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3465154/
0 Response to "what is the unique, simple, and official name assigned to a specific drug for worldwide use?"
Post a Comment